Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
![[18F]DCFPyL in Metastatic Renal Cell Carcinoma: NCT06361810 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
9 min read
[18F]DCFPyL in Metastatic Renal Cell Carcinoma: NCT06361810 Clinical Landscape Report 2026
16 October 2026
NCT06361810 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
UTAA09/17 in Idiopathic Inflammatory Myopathies: NCT06361745 Clinical Landscape Report 2026
16 October 2026
NCT06361745 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Ipilimumab in Microsatellite instability-high colorectal cancer: NCT06362369 Clinical Landscape Report 2026
16 October 2026
NCT06362369 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Letrozole in MSS/pMMR/MSI-L Endometrial Carcinoma: NCT06366347 Clinical Landscape Report 2026
16 October 2026
NCT06366347 clinical landscape for MSS/pMMR/MSI-L Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Relmacabtagene autoleucel in High grade B-cell lymphoma: NCT06365671 Clinical Landscape Report 2026
16 October 2026
NCT06365671 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Metastatic Renal Cell Carcinoma: NCT06364631 Clinical Landscape Report 2026
16 October 2026
NCT06364631 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma recurrent: NCT06365619 Clinical Landscape Report 2026
16 October 2026
NCT06365619 clinical landscape for Melanoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Azenosertib in Uterine Serous Carcinoma: NCT06369155 Clinical Landscape Report 2026
16 October 2026
NCT06369155 clinical landscape for Uterine Serous Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Locally Advanced Soft Tissue Sarcoma: NCT06367075 Clinical Landscape Report 2026
16 October 2026
NCT06367075 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Brigimadlin in Locally Advanced Soft Tissue Sarcoma: NCT06370871 Clinical Landscape Report 2026
16 October 2026
NCT06370871 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Fludarabine Phosphate in Systemic Lupus Erythematosus: NCT06373991 Clinical Landscape Report 2026
16 October 2026
NCT06373991 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19-CD3E-CAR-T cells(Shanghai Changzheng Hospital) in Granulomatosis With Polyangiitis: NCT06373081 Clinical Landscape Report 2026
16 October 2026
NCT06373081 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…